Market open
Elanco/$ELAN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Elanco
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Ticker
$ELAN
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
9,550
Website
Elanco Metrics
BasicAdvanced
$6.2B
Market cap
30.37
P/E ratio
$0.41
EPS
1.42
Beta
-
Dividend rate
Price and volume
Market cap
$6.2B
Beta
1.42
52-week high
$18.80
52-week low
$11.40
Average daily volume
4.9M
Financial strength
Current ratio
2.548
Quick ratio
1.055
Long term debt to equity
66.12
Total debt to equity
66.794
Interest coverage (TTM)
1.02%
Management effectiveness
Return on assets (TTM)
1.18%
Return on equity (TTM)
3.24%
Valuation
Price to earnings (TTM)
30.367
Price to revenue (TTM)
1.389
Price to book
0.95
Price to tangible book (TTM)
-2.93
Price to free cash flow (TTM)
16.628
Growth
Revenue change (TTM)
1.99%
Earnings per share change (TTM)
-117.72%
3-year revenue growth (CAGR)
-2.40%
3-year earnings per share growth (CAGR)
-33.98%
What the Analysts think about Elanco
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Elanco stock.
Elanco Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Elanco Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Elanco News
AllArticlesVideos
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Elanco Animal Health Incorporated of Class Action Lawsuit and Upcoming Deadlines - ELAN
Accesswire·5 days ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 6, 2024 in Elanco Lawsuit - ELAN
Accesswire·6 days ago
ELAN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elanco Animal Health Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewsWire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Elanco stock?
Elanco (ELAN) has a market cap of $6.2B as of December 12, 2024.
What is the P/E ratio for Elanco stock?
The price to earnings (P/E) ratio for Elanco (ELAN) stock is 30.37 as of December 12, 2024.
Does Elanco stock pay dividends?
No, Elanco (ELAN) stock does not pay dividends to its shareholders as of December 12, 2024.
When is the next Elanco dividend payment date?
Elanco (ELAN) stock does not pay dividends to its shareholders.
What is the beta indicator for Elanco?
Elanco (ELAN) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.